Therefore, considering that cells do not appear to become refractory to repeated activation of the NRF2 pathway by drugs, it is possible that cancer cells utilize a non-mutated pathway to support tumor growth in early stages (Perera and Bardeesy, 2011). This evidence concerns the gene NFE2L2 and neoplasm.